Seeking Alpha
0
All posts from Seeking Alpha
Seeking Alpha in Seeking Alpha - Read, Decide, Invest.,

Vivus' Qsymia Headed In The Wrong Direction

New prescription numbers have been released by IMS for Qsymia (see Table 1), the anti-obesity agent from Vivus (VVUS). Qsymia, which has on the market the longest of a trio of products released the past few years, posted a -3.5% decrease. This is remarkable not so much compared to a similar -2.6% decline from the same period last year, but that it followed a 1.4% gain during the prior week that included a holiday. The silver lining is that January 2015's weekly average of 10,097 is above last January's 9,402 average. But while there is no evidence that Qsymia is losing market share to its rivals as of yet, the weekly decrease is a disturbing development.

Table 1. IMS Reported Prescriptions

Qsymia

Belviq

Contrave

Sector

Week Ended

Total

New

Total

New

Total

New

Total

New

01/02/15

9069

5761

9420

6131

4899

4396

23388

16288

01/09/15

10208

6939

11444

7937

6929